$HIMS - Can drop furtherNYSE:HIMS Hims is losing momentum in a big way. There is a possibility that it could drop to $15 - $14 area.
Here are support areas to watch:
- $18.50
- $17
- $15
HIMS trade ideas
Hims at supportAm i the Hims FURU? Maybe... I like it here at $21.50 and believe it's going much higher, the stock isn't even expensive yet. I know a few people taking their GLP-1 compound with great success and no bad sides.
Adding shares at these levels:
- 21.50
- 19.30 (Monthly level)
HIMSBought a starter position, price is at ATH zone, HIMS is strong this year and seems like is not going to pause. This entry is ~40% of my max exposure for a single stock.
Smaller frame analysis in the update below.
HIMS continuation on long sideHIMS breaking out of small consolidation range and may be a continuation of the larger uptrend. It didn’t close above the 20 MA yet. Good amount of activity on Twitter/X on the ticker.
HIMS & HERS HIMS AND HERS NDlet's discuss this idea. what do you think?
leave a comment.
best regards.
HIMS cup and handleThis is a more zoomed out view of my previous chart, these are the cups and handles I like to average into, these usually coincide with great fundamentals and strong growth. The upside projection here is 42-45$.
New position HIMSI have traded this stock in the past and have been waiting for a dip. My plan is to sell covered-calls on this stock. I bought my first LEAP call today at a nice discount and am prepped to average down to the red dashed line if this occurs. I updated weekly fib extensions. The daily stochastic RSI is bottoming, but the weekly is peaking. If we reach around 25 $ on a base this would be forming a huge cup and handle.
Strategy:
2026 LEAP calls ~1k each
15$ strikes, plan to exercise these in two years time
Hopefully by then they will be paid off with premium and the stock will be well above 15$
This is my cash flow strategy for most of my accounts now
HIMS EARNINGS CHART, DO BULLS HAVE ANY UPSIDE REMAINING? Short answer, yep.
LOTS.
Longer answer, this is a key price zone.
Take a look back at the chart as a whole.
It almost looks like it wants to hit 12.5 tomorrow and GAP up earnings.
Hard to say for sure because it's not a stock I watch often.
BUT, it's flashing some bullish signals.
Good luck!
6/21/24 - $hims - Prefer other names, reassess <$15 k?6/21/24 :: VROCKSTAR :: NYSE:HIMS
Prefer other names, reassess <$15 k?
I'm going to keep the comment short bc this one is a sort of obvious "stay on the sidelines" to me.
- stock has had a great bump since announcing they're selling cheap alts to the weight loss juice. cool.
- great gross margins, but when you look at the SG&A (there's no R&D in this biz - which i don't like) the SG&A basically drives 100% of the gross profit. which means, perhaps they get some sort of leverage in the future but it's not happened yet.
- good portfolio that allows a lot of cross/ up selling. but again refer to the prior comment.
- so the cash gen is all we can hang our hats on today (not growth, or some sort of growth multiple), and they dilute a lot (see stock comp) more than the organic cash gen.
- my conclusion is it's a great brand with great traction and recently great news. hence the stock move. but to get this thing higher and sustainably, we need either other larger announcements (unlikely), a few more Q's of results (that will take time), or some sort of buyout (I don't typically use this argument to own something unless the stock is reaching super low lows and there's some form of identifiable R&D value - not the case here - brand sure - but again - no inflection yet).
the $15/shr target to take a look again is still a place i'd unlikely own it, but willing to reassess here. i think stock is probably worth closer to $10 all else equal today, but i know that won't earn me any fans holding the stock (tho i don't care bc i write these notes mainly for myself but publish for benefit of others if they can contribute thoughts that augment the thesis and we can make more money together).
so don't get too hard just yet for this one.
V
Hims & Hers Health, Inc. (NYSE: HIMS)Price Movement: The stock has shown significant volatility, with prices ranging from lows around $3-4 to highs over $25.
Recent Spike: There's a notable price spike in early 2024, where the stock jumped to around $25 before quickly falling back.
Trading Levels: Several price levels are marked, including $19.63, $16.88, and $12.87, which may represent key support or resistance levels.
Trading Strategy: The chart includes annotations suggesting a trading strategy:
"Buy Dip" levels are marked at lower prices ($3.96, around $10.30)
A "Last Buy Position" is noted around the $12 level
A "Sell Position" is marked near the peak of the 2024 spike
A "Point To buy Again" is indicated after the price drop from the peak
Current Trend: After the 2024 spike, the price appears to be in a downtrend, hovering around the $18-19 range.
Long-term View: Despite volatility, the overall trend from 2021 to 2024 appears to be upward, with higher lows and higher highs.
Volume: The chart includes volume bars at the bottom, showing periods of increased trading activity.
This chart suggests that HIMS stock has been volatile but generally trending upward, with opportunities for both buying dips and selling at peaks. The annotations indicate a strategy of buying at lower prices and selling during significant price increases.
HIMS - June 24 Qullamaggie Breakout and Episodic PivotI believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months.
1) Their compounded GLP-1 is significantly cheaper
2) Their platform makes it easier and more accessible to purchase
3) It is lifestyle related so monthly recurring purchases is encouraged
4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing.
As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers
This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting
Source
@moizali - x.com
www.triplewhale.com
Hims is going down before it goes up againThe volume in the upper trend is going down.. so the graph also will go down..
Double top.
Hims (HIMS) Stock Chart Analysis: Observing a Cup and HandleThe HIMS stock chart displays a pattern resembling a cup and handle. If confirmed, technical analysis suggests a possible price target exceeding $24.
While the cup and handle pattern suggests a potential price increase, it's important to consider other factors that can influence the stock price, such as the company's fundamentals, industry trends, and overall market conditions.
It's also crucial to understand the limitations of technical analysis and avoid solely relying on it for investment decisions.
HIMS - June 24 (Broken Characters WIP)This is based on a new strategy that I started working on based on monitoring the larger price landscape and then observe character changes in the price action at key points.
First new high
Initial spike was brought about by news that HIMS would be launching its own branded GLP-1 medicines. These are the revolutionary weight loss drugs like Ozempic.
Second new high
Strong price movement with long full candles, but volume has slightly decreased.
Third new high
Price movement is dulling with significantly smaller candles and low voume
Placed a small short bet that I will scale up if things go my way.
Risk reward is good at 2.47
SL is based on me adding the ATR value on top of my entry
What I am conflicted about is that the larger market regime is bullish
HIMS long 35% UPSIDE POTENTIALFour consecutive higher lows
Bullish check beack at the previous resistance of $12,35
Shares of Hims & Hers Health ($HIMS) Stock Surge 30% Digital pharmacy startup Hims & Hers Health ( NYSE:HIMS ) is introducing compounded GLP-1 weight loss injections, which have been gaining popularity due to supply constraints in the market. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December but did not include GLP-1 medications such as Ozempic and Wegovy. Customers can access the compounded GLP-1 medications via a prescription from a licensed healthcare provider on the Hims & Hers platform.
Hims & Hers ( NYSE:HIMS ) CEO Andrew Dudum said that the company is "confident" that customers will be able to access a consistent supply of the compounded medications. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. The company expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.
The GLP-1 market, dominated by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity. The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.
Hims & Hers ( NYSE:HIMS ) Health's stock price is doing well, thanks to its strong growth and demand for its core products. It has surged by over 30% this year and by more than 112% this year, giving it a market cap of $3.13 billion.
Hims & Hers Health's ( NYSE:HIMS ) business released data this month showing that its total revenue soared by 46% in Q1 to over $278 million, and its subscribers roared by 41% to 1.7 million. This performance makes it one of the fastest-growing companies in the US.
Hims & Hers ( NYSE:HIMS ) expects revenue growth between $292 million and $297 million in Q2 while the adjusted EBITDA will be between $30 and $30 million. The company focuses on some of the biggest industries globally, including sex, anxiety, weight loss, hair, and skin, each of which has a total addressable market worth billions of dollars. Analysts believe that NYSE:HIMS revenue will jump to over $1.2 billion this year followed by $1.5 billion in 2025, which could help justify its hefty valuation.
HIMS a dip to buy?I am starting a DCA on hims, i will be adding as each support level hits (green horizontal). I think this is a good healthcare stocks with growth. The red horizontal is major resistance, once that breaks on a weekly close i will add as well.
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality
focused and helps the customer feel good about him/her- self. It does not have any gender
orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started
a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator
did its thing as the post-earnings action began. I see this stock as a good long to hold into
the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart
horizontal resistance overhead and traders will note that. I see the bullish momentum
continuing perhaps with some healthy ( no pun intended) corrections while underway.
Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
HIMS & HERS Short Before NEW HIGHSGood day traders, I am seeking a short term reversal to close the gap. Once the new low is set, will be looking into loading around the $4.62 area. Remember, entry is everything. Once new low is set, target is set to $13.36.
Hope you enjoy this setup, Happy Trading & BE BLESSED!
HIMS, 3/1-3/8, 9.5% profitOn 2/26/2024, Hims & Hers Health (HIMS) reported earnings of $0.01 per share on revenue of $246.62 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.02 per share on revenue of $245.82 million.
HIMS Hims & Hers Health Options Ahead of EarningsAnalyzing the options chain and the chart patterns of HIMS Hims & Hers Health prior to the earnings report this week,
I would consider purchasing the 9usd strike price Calls with
an expiration date of 2024-3-15,
for a premium of approximately $1.12.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
RiskMastery's Breakout Stocks - HIMS EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential.
In this edition, we'll be looking at NYSE:HIMS ...
I believe this code is at a point of potential volatility.
If price can hold above $10.05 ... Bullish potential may be unlocked.
My key upside targets include:
- $11.24 (Conservative)
- $12.47 (Medium)
- $14.59 (Aggressive)
If however price falls below $8.19 ... Bearish risk potential may be unlocked.
(My key risk targets - C, M,& A - are as noted on the chart)
Enjoy, and I look forward to being of further service into the future.
If you'd like to connect, feel free to reach out and comment below.
Mr RM | Risk Mastery
Disclaimer:
This post is intended for educational purposes only - Publicly available RiskMastery information & content is not intended to be financial advice in any shape or form. Please do your own research and seek advice from a licensed professional before acting on any of the information contained within this post. This post is not a solicitation or recommendation to buy, sell or hold any positions in any financial instrument. All demonstrated trades are merely incidental to the educational training RiskMastery aims to provide. You are solely responsible for your own investment and trading decisions, of which should be made only according to your own opinion, knowledge and experience. You should not rely on any of the information contained on this site or contained in any RiskMastery material on any website or platform. You assume the sole risk of any trade or investment you elect to make. RiskMastery and affiliates shall not be liable to you for any monetary losses or any other damages incurred directly or indirectly, from your use, reliance or reference of RiskMastery materials, content and educational information. Thank you for your understanding and cooperation - We look forward to working with you into the future to navigate the fine line of trading and investment success.
